Athira Pharma, Inc. (NASDAQ:ATHA) has a beta value of 0 and has seen 1,025,792 shares traded in the last trading session. The company, currently valued at $409.45 Million, closed the last trade at $11 per share which meant it gained $0.46 on the day or 4.36% during that session. The ATHA stock price is -216.27% off its 52-week high price of $34.79 and 11.82% above the 52-week low of $9.7. If we look at the company’s 10-day average daily trading volume, we find that it stood at 761.34 Million shares traded. The 3-month trading volume is 1.13 Million shares.
The consensus among analysts is that Athira Pharma, Inc. (ATHA) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.34.
Sporting 4.36% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jul 06 when the ATHA stock price touched $11.15- or saw a rise of 1.35%. Year-to-date, Athira Pharma, Inc. shares have moved -67.88%, while the 5-day performance has seen it change 3.29%. Over the past 30 days, the shares of Athira Pharma, Inc. (NASDAQ:ATHA) have changed -45%. Short interest in the company has seen 1.69 Million shares shorted with days to cover at 1.5.
Wall Street analysts have a consensus price target for the stock at $41.5, which means that the shares’ value could jump 277.27% from current levels. The projected low price target is $36 while the price target rests at a high of $51. In that case, then, we find that the current price level is +363.64% off the targeted high while a plunge would see the stock lose 227.27% from current levels.
Athira Pharma, Inc. (ATHA) estimates and forecasts
Earnings growth for 2021 is a modest -915.4%.
Athira Pharma, Inc. (NASDAQ:ATHA)’s Major holders
Insiders own 4.64% of the company shares, while shares held by institutions stand at 70.93% with a share float percentage of 74.39%. Investors are also buoyed by the number of investors in a company, with Athira Pharma, Inc. having a total of 100 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 3.43 Million shares worth more than $63.04 Million. As of March 30, 2021, Perceptive Advisors Llc held 9.2% of shares outstanding.
The other major institutional holder is RTW Investments LP, with the holding of over 2.65 Million shares as of March 30, 2021. The firm’s total holdings are worth over $48.81 Million and represent 7.13% of shares outstanding.
Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.
Add them to your watchlist before they take off!
Also the top two Mutual Funds that are holding company’s shares are Franklin Strategic Series-Franklin Biotechnology Discove and Vanguard Total Stock Market Index Fund. As of April 29, 2021, the former fund manager holds about 2.09% shares in the company for having 779576 shares of worth $15.34 Million while later fund manager owns 462.98 Thousand shares of worth $8.52 Million as of March 30, 2021, which makes it owner of about 1.24% of company’s outstanding stock.